Final hours! Save up to 55% OFF InvestingProCLAIM SALE

Shionogi says COVID pill trial shows reduction in symptoms

Published 09/27/2022, 11:02 PM
Updated 09/28/2022, 01:07 PM
© Reuters. FILE PHOTO: Isao Teshirogi, President and CEO at Shionogi & Co Ltd, speaks during an interview with Reuters in Tokyo, Japan June 11, 2019.  REUTERS/Issei Kato
JP225
-
PFE
-

TOKYO (Reuters) -Japan's Shionogi & Co Ltd said on Wednesday its oral treatment for COVID-19 demonstrated a significant reduction in symptoms compared with a placebo in a Phase III trial in Asia.

The drug, a protease inhibitor known as ensitrelvir, met its primary endpoint in a trial conducted among predominantly vaccinated patients with mild to moderate cases of COVID-19, the company said in a statement.

Shionogi's shares reversed an early decline after the announcement, closing 1.1% higher in Tokyo versus a 1.5 drop in the benchmark Nikkei gauge.

Ensitrelvir met the trial's goal in reducing five key symptoms of the Omicron variant of COVID-19 within 72 hours of onset, the company said.

Regulatory authorities in Japan previously denied emergency approval for use of the pill, saying they wanted to see more data on its effectiveness. There are also concerns the drug could pose risk to pregnancies, based on results from animal studies.

Shionogi said it has shared top-line data from the Phase III study with Japanese regulators as part of deliberations on approval of the drug.

Shionogi has global aspirations for the drug, also known as S-217622 and by the brand name Xocova, which would compete with COVID-19 pills from Pfizer Inc (NYSE:PFE) and Merck & Co Inc that have already been approved in Japan and elsewhere.

© Reuters. FILE PHOTO: Isao Teshirogi, President and CEO at Shionogi & Co Ltd, speaks during an interview with Reuters in Tokyo, Japan June 11, 2019.  REUTERS/Issei Kato

The company has signed an agreement to sell about a million doses to the government, pending the drug's approval.

Chief Executive Isao Teshirogi has said annual production of the drug could reach 10 million doses. The firm has received U.S. government support for a global Phase III trial.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.